Stefanie Becker

Risk of Epilepsy and Factors Associated With Time to Seizure Remission in Anti-LGI1 Encephalitis

Tobias Baumgartner, Moritz Freyberg, Lucia Campetella, Yvette S. Crijnen et autres

BACKGROUND AND OBJECTIVES: Autoimmune encephalitis (AIE) with anti-leucine-rich glioma-inactivated 1 (LGI1) antibodies typically manifests with subacute cognitive deficits, seizures, and psychiatric symptoms, mostly in older adults. Immunotherapy (IT) leads to the cessation of seizures in most patients, yet some develop AIE-associated epilepsy …

de, fr, nl, at, ch (code pays fourni par la source)

Early Treatment With Intravenous Immunoglobulins and Outcomes of Patients With Anti-IgLON5 Disease

Thomas Grüter, Carles Gaig, Yvette S. Crijnen, Maarten J. Titulaer et autres

Importance: Anti-IgLON5 disease is an autoimmune encephalopathy that often leads to severe disability or death. The efficacy of immunotherapy remains unknown. Objective: To investigate whether early immunotherapy is associated with disability and death in anti-IgLON5 disease. Design, Setting, and Participants: This retrospective, …

de, es, nl, at, fr (code pays fourni par la source)

Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer Disease: Intersocietal Recommendations for Their Appropriate Use in Switzerland

Ansgar Felbecker, Olivier Rouaud, Gilles Allali, Marc Sollberger et autres

The association of Swiss Memory Clinics (SMC) provides intersocietal recommendations for the use of anti-amyloid monoclonal antibodies (mAbs) in Switzerland. The recommendations are the result of extensive interdisciplinary discussions in a group of Swiss dementia experts from August 2023 until December 2024. …

ch, us, ee, jo (code pays fourni par la source)

Conference report: Trends, new technologies and implications for dementia diagnostics, treatment and care in Switzerland

Julius Popp, Reto W. Kressig, Mélanie Bieler-Aeschlimann, Miriam Rabl et autres

Dementia diseases represent a major burden for the directly affected people, their relatives and modern society. Despite considerable efforts in recent years, early and accurate disease diagnosis and monitoring is still a challenge while no cure is available in most cases. New …

ch, de (code pays fourni par la source)

[Alzheimer's disease - system prepardeness in the context of new developments].

Rafael Meyer, Andreas U. Monsch, Gilles Allali, Nadège Barro-Belaygues et autres

INTRODUCTION: The possible authorisation of new monoclonal antibody therapies for Alzheimer's disease poses challenges for healthcare systems worldwide. In this paper, the Swiss Memory Clinics association (SMC) analyses the available resources and identifies potential health care shortages. Overcoming potential bottlenecks is a …

ch, us, kr, be (code pays fourni par la source)

[The Swiss Memory Clinics recommendations for the treatment of dementia].

Stefan Klöppel, Tatjana Meyer-Heim, Michael M. Ehrensperger, Angelika Rüttimann et autres

jp, ch, us, au, de, nl (code pays fourni par la source)

Different pain phenotypes are associated with anti-Caspr2 autoantibodies

Patrik Greguletz, Maria Plötz, Carolin Baade‐Büttner, Christian G. Bien et autres

Autoantibodies against contactin-associated protein 2 (Caspr2) not only induce limbic autoimmune encephalitis but are also associated with pain conditions. Here, we analyzed clinical data on pain in a large cohort of patients included into the German Network for Research in Autoimmune Encephalitis. …

de, at (code pays fourni par la source)

[Recommendations for the diagnostic and therapy of behavioural and psychological symptoms of dementia (BPSD)].

Egemen Savaskan, Dan Georgescu, Stefanie Becker, Brigitte Benkert et autres

INTRODUCTION: The «Recommendations for the Diagnosis and Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD)» were developed in parallel with the Swiss National Dementia Strategy 2014-2019 under the auspices of the Swiss Society for Geriatric Psychiatry and Psychotherapy (SGAP) and mark …

ch, ee, kr (code pays fourni par la source)

Position Statement on Anti-Dementia Medication for Alzheimer’s Disease by Swiss Stakeholders

Giovanni B. Frisoni, Jean‐Marie Annoni, Stefanie Becker, Tim Brockmann et autres

The present document represents the position of Swiss health-care associations, clinical and research centers, research-supporting foundations, and the association Alzheimer Switzerland regarding the care of persons with dementia and Alzheimer’s disease. We claim that dementia is not part of normal aging but …

ch (code pays fourni par la source)

Conference report: dementia research and care and its impact in Switzerland

Thomas Leyhe, Mathias Jucker, Tobias Nef, Marc Sollberger et autres

In October 2019, a Swiss panel of experts met for the Dementia Summit in Brunnen, Switzerland, to discuss the latest scientific findings on basic and clinical research, as well as practical and political approaches to the challenges of dementia disorders in Switzerland. …

ch, de, si (code pays fourni par la source)

Bedeutung erblicher Faktoren für die Variabilität der Pharmakokinetik von Arzneimitteln im Vergleich zwischen oraler und intravenöser Dosierung anhand einer Zwillingsstudie

Stefanie Becker

The main objective of this study was to investigate hereditary and non-hereditary differences in the activity of the OATP1B1 transporter and the CYP2C9 and CYP3A4 enzymes between oral and intravenous drug dosing. It was conducted based on an open label, non-randomized pharmacokinetic …

Integrative mosquito intervention strategies

Mareike Heinig, Stefanie Becker, Michael E. Stern, Kwang‐Zin Lee